Informatics approaches to assessing patient frailty in surgical care
评估外科护理中患者虚弱程度的信息学方法
基本信息
- 批准号:10242206
- 负责人:
- 金额:$ 61.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AbdomenAcuteAddressAgeAgingAlgorithmsAmericanBiologicalCaringChronic DiseaseChronologyClinicalCodeComplexComputer softwareConsumptionCounselingDataData AnalysesData SetDecision MakingDiagnosticElderlyElectronic Health RecordExhibitsFutureGoalsHospital CostsHospital MortalityHospitalsInfiltrationInformaticsInterventionLaboratoriesLength of StayManualsMeasuresMethodologyModelingMorbidity - disease rateMuscleMuscular AtrophyNational Institute on AgingOperative Surgical ProceduresPathway interactionsPatient-Focused OutcomesPatientsPerformancePerioperativePerioperative CarePhysical FunctionPhysiologicalPopulationPopulation HeterogeneityPostoperative PeriodPredictive ValueProcessResearchRiskRisk FactorsScanningSeverity of illnessSkeletal MuscleStandardizationSumSurgical complicationTechnologyTimeValidationX-Ray Computed Tomographyadverse outcomebaseclinical carecomputer sciencecostdigitalelectronic datafrailtyfunctional statushigh riskhospital readmissionimprovedinnovationinpatient surgerymortalitymuscle formolder patientpatient responseperformance testspostoperative recoverypredictive modelingprofiles in patientsprogramsprospectiverisk stratificationsarcopeniasecondary analysisshared decision makingstressorsurgery outcomesurgical risktool
项目摘要
ABSTRACT
Surgical complications are common, costly, and deadly. Older patients are at high risk of adverse surgical
outcomes, especially when they exhibit frailty. Frailty is a state of decreased physiologic reserve and loss of
capacity to adapt to stressors. Over the past decade, while frailty has been increasingly recognized as an
important risk factor for poor surgical outcomes, integration of a standardized frailty metric into clinical care has
not been achieved. A key barrier is that existing frailty assessments are not standardized, objective, or widely
available, limiting their routine application in surgical decision-making. With the long-term goal of improving
surgical care for older adults, we will evaluate two “e-frailty” metrics that can be automatically derived from
electronic or digital data that are already collected as part of routine clinical care. These e-frailty metrics
include, first, granular patient profiles of electronic health record (EHR) data (risk scores based on claims data
or on physiologic and laboratory values), and second, muscle loss assessed from pre-surgical computed
tomography (CT) scans (low skeletal muscle mass, known as sarcopenia, and fatty infiltration into muscle
indicative of reduced physical function, known as myosteatosis). In Aim 1, we will calculate these two e-frailty
metrics among a diverse population of over 41,000 abdominal surgical patients; characterize the overlap
between patients designated as frail by the two e-frailty metrics; and evaluate their associations with 30-day
readmission and other adverse surgical outcomes (30-day and 1-year mortality, complications, non-home
discharge, and length of stay >7 days). In Aim 2, we will compare the performance of e-frailty metrics for
predicting 30-day readmission and other adverse surgical outcomes to that of standard risk stratification tools
(acute and chronic illness severity metrics) already embedded in EHRs today using cross-validation and an
independent validation dataset of over 14,000 more recent abdominal surgeries. In Aim 3, we will examine
whether e-frailty metrics modify the benefits that patients derive from achieving postoperative targets -including
early and sustained mobilization- in one of the largest Enhanced Recovery After Surgery (ERAS) programs in
the nation. We will examine e-frailty metrics as salient indicators of biologic age for predicting morbidity and
mortality. In sum, e-frailty metrics show great promise for identifying high-risk patients in the surgical domain,
but they need to be integrated within clinical workflows to be scalable and sustainable. This proposal will
compute standardized e-frailty metrics automatically derived from EHR data and provide new information
regarding the potential value of these e-frailty metrics for improving surgical care for older adults. This study
will also lay the groundwork for future prospective interventions integrating e-frailty metrics into clinical care to
improve risk stratification and counseling of patients considering surgery and enhance perioperative care for
frail surgical patients.
抽象的
手术并发症很常见、昂贵且致命。老年患者手术不良的风险很高
结果,尤其是当他们表现出脆弱时。虚弱是一种生理储备减少和丧失能力的状态
适应压力源的能力。在过去的十年中,虽然衰弱已越来越被认为是一种
手术结果不佳的重要风险因素,将标准化衰弱指标纳入临床护理已
没有实现。一个主要障碍是现有的衰弱评估不够标准化、客观或广泛
可用,限制了它们在外科决策中的常规应用。以改善的长期目标
对于老年人的手术护理,我们将评估两个“电子衰弱”指标,这些指标可以自动导出
作为常规临床护理的一部分已经收集的电子或数字数据。这些电子脆弱性指标
首先,包括电子健康记录 (EHR) 数据的详细患者档案(基于索赔数据的风险评分)
或根据生理和实验室值),第二,根据手术前计算得出的肌肉损失评估
断层扫描 (CT) 扫描(骨骼肌质量低,称为肌肉减少症,以及脂肪浸润肌肉
表明身体功能下降,称为肌脂肪变性)。在目标 1 中,我们将计算这两个电子脆弱性
超过 41,000 名腹部手术患者的不同人群的指标;表征重叠
根据两个电子衰弱指标指定为衰弱的患者之间;并评估他们与 30 天的关联
再入院和其他不良手术结果(30 天和 1 年死亡率、并发症、非家庭
出院,且住院时间 >7 天)。在目标 2 中,我们将比较电子脆弱性指标的性能
根据标准风险分层工具预测 30 天再入院和其他不良手术结果
(急性和慢性疾病严重程度指标)现已通过交叉验证和
超过 14,000 例近期腹部手术的独立验证数据集。在目标 3 中,我们将检查
电子衰弱指标是否会改变患者从实现术后目标中获得的益处,包括
早期和持续的活动——这是美国最大的加速康复外科 (ERAS) 计划之一
国家。我们将研究电子衰弱指标作为生物年龄的显着指标,用于预测发病率和
死亡。总之,电子衰弱指标在识别外科领域的高危患者方面显示出巨大的前景,
但它们需要集成到临床工作流程中才能实现可扩展和可持续。该提案将
计算从 EHR 数据自动得出的标准化电子衰弱指标并提供新信息
关于这些电子衰弱指标对于改善老年人手术护理的潜在价值。这项研究
还将为未来将电子衰弱指标纳入临床护理的前瞻性干预措施奠定基础
改善考虑手术的患者的风险分层和咨询,并加强围手术期护理
体弱的手术患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Marjorie Cespedes Feliciano其他文献
Elizabeth Marjorie Cespedes Feliciano的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth Marjorie Cespedes Feliciano', 18)}}的其他基金
Understanding the role of adiposity and adipokine-related RNA expression in the tumor microenvironment on breast cancer outcomes in a racially and ethnically diverse sample
了解肿瘤微环境中肥胖和脂肪因子相关 RNA 表达对种族和民族多样化样本中乳腺癌结果的作用
- 批准号:
10602753 - 财政年份:2022
- 资助金额:
$ 61.12万 - 项目类别:
Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors
身体成分和乳腺癌生存:乳腺肿瘤中的免疫和代谢生物标志物
- 批准号:
10029647 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors
身体成分和乳腺癌生存:乳腺肿瘤中的免疫和代谢生物标志物
- 批准号:
10198876 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
D3-creatine dilution to determine skeletal muscle mass in colon cancer patients
D3-肌酸稀释液测定结肠癌患者的骨骼肌质量
- 批准号:
10337029 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
Informatics approaches to assessing patient frailty in surgical care
评估外科护理中患者虚弱程度的信息学方法
- 批准号:
10407652 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors
身体成分和乳腺癌生存:乳腺肿瘤中的免疫和代谢生物标志物
- 批准号:
10425385 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
D3-creatine dilution to determine skeletal muscle mass in colon cancer patients
D3-肌酸稀释液测定结肠癌患者的骨骼肌质量
- 批准号:
10579981 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
Informatics approaches to assessing patient frailty in surgical care
评估外科护理中患者虚弱程度的信息学方法
- 批准号:
10652340 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors - Disparities Supplement
身体成分和乳腺癌生存:乳腺肿瘤中的免疫和代谢生物标志物 - Disparities Supplement
- 批准号:
10712034 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors
身体成分和乳腺癌生存:乳腺肿瘤中的免疫和代谢生物标志物
- 批准号:
10665682 - 财政年份:2020
- 资助金额:
$ 61.12万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 61.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 61.12万 - 项目类别:
Standard Grant














{{item.name}}会员




